PERCHERON THERAPEUTICS LIMITED Financials Percheron Therapeutics Limited
Equities
PER
AU0000317281
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.068 AUD | +6.25% |
|
-6.85% | +15.25% |
| Feb. 28 | Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| 2023 | Dimerix Appoints Nonexecutive Chair | MT |
Valuation
| Fiscal Period: Giugno | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 36.17 | 112 | 50.16 | 39.49 | 61.31 | - | - |
| Enterprise Value (EV) 1 | 36.17 | 106.3 | 31.15 | 28.52 | 55.21 | 43.9 | 42.8 |
| P/E ratio | - | -13.1 x | - | -3.47 x | -3.58 x | -1.61 x | -2.27 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 46.9 x | 176 x | 27.7 x | 20.1 x | 17.2 x | 11.7 x | 17.5 x |
| EV / Revenue | 46.9 x | 167 x | 17.2 x | 14.5 x | 15.5 x | 8.36 x | 12.2 x |
| EV / EBITDA | - | -13.4 x | -5.46 x | -2.53 x | -3.17 x | -1.4 x | -1.83 x |
| EV / FCF | - | -18,195,824 x | -3,989,429 x | -3,486,569 x | - | - | - |
| FCF Yield | - | -0% | -0% | -0% | - | - | - |
| Price to Book | - | 19.5 x | 2.37 x | 3.96 x | 4.02 x | 1.82 x | 3.55 x |
| Nbr of stocks (in thousands) | 488,785 | 574,476 | 668,794 | 669,315 | 901,545 | - | - |
| Reference price 2 | 0.0740 | 0.1950 | 0.0750 | 0.0590 | 0.0680 | 0.0680 | 0.0680 |
| Announcement Date | 8/26/20 | 8/25/21 | 8/31/22 | 8/25/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.7716 | 0.6368 | 1.812 | 1.965 | 3.56 | 5.25 | 3.5 |
| EBITDA 1 | - | -7.947 | -5.711 | -11.28 | -17.4 | -31.31 | -23.45 |
| EBIT 1 | - | -8.05 | -5.8 | -11.37 | -17.5 | -31.36 | -23.5 |
| Operating Margin | - | -1,264.04% | -320.07% | -578.78% | -491.57% | -597.38% | -671.43% |
| Earnings before Tax (EBT) 1 | - | -8.061 | - | -11.38 | -17.2 | -14.6 | -14.4 |
| Net income 1 | - | -8.061 | - | -11.38 | -17.2 | -31.12 | -23.27 |
| Net margin | - | -1,265.72% | - | -579.19% | -483.15% | -592.75% | -664.86% |
| EPS 2 | - | -0.0149 | - | -0.0170 | -0.0190 | -0.0421 | -0.0300 |
| Free Cash Flow | - | -5.843 | -7.809 | -8.181 | - | - | - |
| FCF margin | - | -917.42% | -430.95% | -416.37% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 8/26/20 | 8/25/21 | 8/31/22 | 8/25/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2021 S2 | 2024 S1 |
|---|---|---|
| Net sales 1 | - | 1.2 |
| EBITDA 1 | -6.01 | -4.693 |
| EBIT 1 | -6.01 | -4.741 |
| Operating Margin | - | -395.02% |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | - | -4.743 |
| Net margin | - | -395.24% |
| EPS 2 | - | -0.006600 |
| Dividend per Share | - | - |
| Announcement Date | 8/25/21 | 2/28/24 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 5.71 | 19 | 11 | 6.1 | 17.4 | 18.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -5.84 | -7.81 | -8.18 | - | - | - |
| ROE (net income / shareholders' equity) | - | -157% | -43.3% | - | - | - | -82.6% |
| ROA (Net income/ Total Assets) | - | - | -39.5% | - | - | - | -73.5% |
| Assets 1 | - | - | - | - | - | - | 31.66 |
| Book Value Per Share 2 | - | 0.0100 | 0.0300 | 0.0100 | 0.0200 | 0.0400 | 0.0200 |
| Cash Flow per Share 2 | - | -0.0100 | -0.0100 | -0.0100 | -0.0200 | -0.0400 | -0.0300 |
| Capex 1 | - | 0.01 | 0 | 0.03 | 0.1 | - | - |
| Capex / Sales | - | 1.31% | 0.22% | 1.49% | 2.81% | - | - |
| Announcement Date | 8/26/20 | 8/25/21 | 8/31/22 | 8/25/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.068
AUD
Average target price
0.25
AUD
Spread / Average Target
+267.65%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +15.25% | 39.98M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PER Stock
- Financials Percheron Therapeutics Limited
